Ocular Therapeutix Inc [OCUL] stock prices are down -0.99% to $15.95 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The OCUL shares have gain 41.78% over the last week, with a monthly amount glided 47.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ocular Therapeutix Inc [NASDAQ: OCUL] stock has seen the most recent analyst activity on September 15, 2025, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $21. On March 18, 2025, RBC Capital Mkts initiated with an Outperform rating and assigned a price target of $17 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $15 on March 11, 2025. Scotiabank initiated its recommendation with a Sector Outperform. TD Cowen upgraded its rating to Buy for this stock on June 20, 2024, and upped its price target to $11.
The stock price of Ocular Therapeutix Inc [OCUL] has been fluctuating between $5.78 and $16.44 over the past year. Currently, Wall Street analysts expect the stock to reach $26.25 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $15.95 at the most recent close of the market. An investor can expect a potential return of 64.58% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
The Ocular Therapeutix Inc [NASDAQ:OCUL] reported sales of 55.78M for trailing twelve months, representing a drop of -5.71%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -4.5%, Pretax Profit Margin comes in at -4.48%, and Net Profit Margin reading is -4.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is -0.87 and Total Capital is -0.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.58 points at the first support level, and at 15.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.32, and for the 2nd resistance point, it is at 16.68.
Ratios To Look Out For
It’s worth pointing out that Ocular Therapeutix Inc [NASDAQ:OCUL]’s Current Ratio is 7.85. On the other hand, the Quick Ratio is 7.78, and the Cash Ratio is 6.99. Considering the valuation of this stock, the price to sales ratio is 60.92, the price to book ratio is 10.81.
Transactions by insiders
Recent insider trading involved Nayak Sanjay, Chief Strategy Officer, that happened on Nov 24 ’25 when 1878.0 shares were sold. Dugel Pravin completed a deal on Nov 24 ’25 to sell 19530.0 shares. Meanwhile, Chief Development Officer Kaiser Peter sold 3007.0 shares on Nov 24 ’25.
